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Abstract
Aims/hypothesis Gene–macronutrient interactions may contribute to the development of type 2 diabetes but research evidence to
date is inconclusive. We aimed to increase our understanding of the aetiology of type 2 diabetes by investigating potential
interactions between genes and macronutrient intake and their association with the incidence of type 2 diabetes.
Methods We investigated the influence of interactions between genetic risk scores (GRSs) for type 2 diabetes, insulin resistance
and BMI and macronutrient intake on the development of type 2 diabetes in the European Prospective Investigation into Cancer
and Nutrition (EPIC)-InterAct, a prospective case-cohort study across eight European countries (N = 21,900 with 9742 incident
type 2 diabetes cases). Macronutrient intake was estimated from diets reported in questionnaires, including proportion of energy
derived from total carbohydrate, protein, fat, plant and animal protein, saturated, monounsaturated and polyunsaturated fat and
dietary fibre. Using multivariable-adjusted Cox regression, we estimated country-specific interaction results on the multiplicative
scale, using random-effects meta-analysis. Secondary analysis used isocaloric macronutrient substitution.
Results No interactions were identified between any of the three GRSs and any macronutrient intake, with low-to-moderate
heterogeneity between countries (I2 range 0–51.6%). Results were similar using isocaloric macronutrient substitution analyses
and when weighted and unweighted GRSs and individual SNPs were examined.
Conclusions/interpretation Genetic susceptibility to type 2 diabetes, insulin resistance and BMI did not modify the association
between macronutrient intake and incident type 2 diabetes. This suggests that macronutrient intake recommendations to prevent
type 2 diabetes do not need to account for differences in genetic predisposition to these three metabolic conditions.
Keywords BMI . Body mass index . Diabetes . Diet . Dietary fibre . Genetic risk score . GRS . Insulin resistance . Interaction .
Macronutrient
Abbreviations
EPIC European Prospective Investigation into Cancer and
Nutrition
GRS Genetic risk score
Introduction
Genetic and environmental factors, including diet, contribute
to the development of type 2 diabetes. Among dietary
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components, an emphasis on macronutrient composition has
dominated public health dietary recommendations for de-
cades, with guidance on the optimal per cent of energy to be
consumed from carbohydrate, fat and protein. More recent
dietary guidance also acknowledges the importance of macro-
nutrient quality. For instance, evidence supporting the cardio-
metabolic benefits of replacing dietary saturated fat with poly-
unsaturated fat has led to guidance concerning fat subtype or
quality. There is also a substantial genetic contribution to type
2 diabetes, with the heritability estimated to be 40–80%.
There has been increasing interest in whether this genetic
susceptibility may influence how macronutrient intake affects
the development of type 2 diabetes (gene–macronutrient inter-
action) and whether this may support the notion of
‘personalised’ or ‘precision’ nutrition. However, our recent
systematic review failed to confirm any interactions via repli-
cation using similar cohorts [1]. Genetic risk scores (GRSs)
may help to explain more variance for type 2 diabetes and
prove better than candidate gene approaches to improve statis-
tical power to detect potential interactions. Yet, there is a pau-
city of studies examining gene–macronutrient interaction using
a GRS approach. Therefore, we aimed to increase our under-
standing of the aetiology of type 2 diabetes by investigating
potential interactions between genes and macronutrient intake
and their association with the incidence of type 2 diabetes
using GRSs for type 2 diabetes, insulin resistance and BMI.
Methods
Study population and case definition and ascertainment
EPIC-InterAct is a case-cohort study, nested within the
•
•
•
•
•
Fig. 1 Association between macronutrient intake and the incidence of
type 2 diabetes (T2D) stratified by high or low GRS for T2D (a),
insulin resistance (b) and BMI (c): EPIC-InterAct study. GRS
categorisation: T2D high ≥52, low <52 risk alleles; insulin resistance
high ≥55, low <55 risk alleles; BMI high ≥91, low <91 risk alleles.
Macronutrients are modelled per SD difference in intake (see Table 1
for the SD for each macronutrient). Carbohydrate intake adjusted for
age (underlying time scale), sex, centre, education, physical activity,
smoking status, sex-specific alcohol category, BMI, total energy intake,
dietary protein, PUFA:SFA ratio, dietary fibre and first five principal
components for population stratification. Intake of protein and its
subtypes adjusted for age (underlying time scale), sex, centre, physical
activity, smoking status, sex-specific alcohol categories, BMI, waist–hip
ratio, total energy intake, dietary fibre, SFA, MUFA, PUFA, soft drinks,
tea and coffee (not adjusted for carbohydrates [i.e. a substitution model]),
education and first five principal components for population stratification.
Intake of fat and its subtypes adjusted for age (underlying time scale), sex,
centre, physical activity, smoking status, sex-specific alcohol categories,
BMI, total energy intake, dietary fibre, magnesium, iron, vitamin C, leafy
vegetables, tea, coffee, education and first five principal components for
population stratification. Intake of dietary fibre and its subtypes adjusted
for age (underlying time scale), sex, centre, physical activity, smoking
status, sex-specific alcohol category, total energy intake, dietary
carbohydrates, magnesium, SFA, education level and first five principal
components for population stratification. Fibre subtypes were mutually
adjusted. The interaction analysis for BMI GRS does not adjust for BMI.
Interactions were considered statistically significant if p < 0.0015 (0.05/
33 tests). Example of interpretation: the HR of 1 SD difference in fruit
fibre on incident T2D is 1.03 in those who have the highest genetic
predisposition for T2D and 1.01 for those with lower genetic
predisposition for T2D. There was no statistically significant difference
between those with different genetic predispositions for T2D. Black
circles, high GRS; white circles, low GRS. MUFA, monounsaturated
fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid
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European Prospective Investigation into Cancer and
Nutrition (EPIC) study, described previously [2]. From
340,234 eligible participants across eight European coun-
tries, EPIC-InterAct included 27,779 healthy participants,
consisting of 12,403 incident type 2 diabetes cases and a
representative subcohort of 16,154 participants (including
778 individuals who developed type 2 diabetes during fol-
low-up, according to the design of a case-cohort study).
Macronutrient GRS group Macronutrient GRS groupHR (95% CI) HR (95% CI)
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Cases of type 2 diabetes were ascertained via self-report of a
diagnosis by a medical doctor or use of glucose-lowering
medication noted in a lifestyle questionnaire and verified by
one or more independent sources (linkage to primary and
secondary care registers, medication use from prescription
registers, hospital admission, mortality data and individual
medical record review in some centres). The study period
was from baseline (1991–1997) until the censor date of 31
December 2007. Our current analyses were based on 21,900
adults with available genome-wide genotyping and dietary
data (electronic supplementary material [ESM] Fig. 1).
Participants gave written informed consent and ethical
approval was obtained at each participating research centre.
Exposure and covariates Genotyping was performed on the
Illumina 660 W-Quad BeadChip (http://emea.support.
illumina.com/array/array_kits/human660w-quad_dna_
analysis_kit.html) or Illumina HumanCore Exome chip
(http://emea.support.illumina.com/array/array_kits/
humancore_exome_beadchip_kit.html) arrays, with
imputation to the Haplotype Reference Consortium using
IMPUTE v2.3.2 (http://mathgen.stats.ox.ac.uk/impute/
impute_v2.html). All SNPs met quality control criteria
for genotyping call rate (≥95%) or were well imputed
(info ≥ 0.99). We generated unweighted GRSs for type 2
diabetes, insulin resistance and BMI by summing up the
number of risk alleles for each trait using SNPs that reached
genome-wide significance for the respective traits in
published meta-analyses investigating European populations
[3–5]. Habitual self-reported macronutrient intakes were
estimated from country-specific baseline dietary assessments
and food composition derived from the EPIC Nutrient
DataBase. We examined macronutrient quantity (total
carbohydrate, fat and protein intake) and quality (dietary fibre,
saturated, monounsaturated and polyunsaturated fatty acids,
and animal and plant protein).
Statistical analysis Variables with <30% missing data were
imputed using multiple imputation by chained equations in
Stata (v14 [StataCorp, College Station, TX, USA]) (ESM
Table 1). After confirming no obvious between-imputation var-
iation across 20 multiple imputation datasets, a single imputa-
tion was used for analyses because of computational efficiency
(ESM Fig. 2). Exposures were treated as continuous variables
(GRS per SD difference and macronutrient densities as 5% of
total energy intake per day and 1 g/4.18 MJ [or per 1000 kcal]
per day for dietary fibre) to maximise statistical power. Crude
and multivariable-adjusted Prentice-weighted Cox regression
models were constructed within country (for macronutrient
main associations) and by genotyping chip (for GRS main as-
sociations and gene–macronutrient interactions). Given the
over-representation of cases in the case-cohort analysis, the
cases within and outside the subcohort were weighted
differently using the weighting scheme proposed by Prentice
[6]. Country-specific HRs for the variables of interest were
combined across countries using random-effects meta-analysis
and, where appropriate, meta-analysed across genotyping chip.
Multiplicative interaction was evaluated by fitting a product
term between the genetic and macronutrient exposures. For
consistency, modelling was based as closely as possible on
the models used in previous EPIC-InterAct analyses for carbo-
hydrate [7], protein [8] and dietary fibre [9] (ESM Methods).
Between-country heterogeneity was quantified by the I2 value
and p for heterogeneity was derived from the Cochran-Q test.
Further secondary interaction analysis was conducted
for each SNP within all three GRSs. We also examined
the effect of isocaloric macronutrient substitution on these
interactions using the multivariate nutrient density model
(ESM Table 2).
For visualisation, we also estimated the HR for each dietary
factor stratified by high and low GRS groups (Fig. 1).
Stata v14 was used for analysis. Numerical p values for
interaction were reported; however, the threshold for deter-
mining statistical significance for interactions between GRS
and macronutrient intake was ≤0.0015 (0.05/33 tests) to ac-
count for the effective number of independent tests among
correlated exposures (ESM Table 3).
Results
Table 1 shows the baseline characteristics, with more detail
previously published [9], and main associations for macronu-
trient intake and GRSs. Positive associations with incident
type 2 diabetes were observed for the proportion of energy
from overall protein and animal protein intake (Table 1).
However, these associations were not significant after ac-
counting for multiple testing. No statistically significant inter-
actions were identified–the association between the propor-
tion of energy derived from the intake of each macronutrient
and incident type 2 diabetes did not differ significantly by
GRS for type 2 diabetes (pinteraction ≥ 0.20), insulin resistance
(pinteraction ≥ 0.21) or BMI (pinteraction ≥ 0.22) (Fig. 1 and ESM
Table 4). There was low-to-moderate heterogeneity between
countries in EPIC-InterAct (I2 range 0–51.6%) (ESM
Table 4).
Secondary analysis Results did not change substantially
when: (1) using weighted GRSs; (2) modelling isocalo-
ric macronutrient substitution (pinteraction ≥ 0.17) (see
model 5 in ESM Table 2); or (3) when examining
interactions with each individual SNP while accounting
for isocaloric macronutrient substitution (ESM Fig. 3
and ESM Table 5). The results were similar when our
current analyses based on imputed data were compared
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with a complete case analysis (ESM Table 6 provides
an example).
Discussion
In this large, multi-country, population-based prospective
study from Europe, we found no statistically significant inter-
actions between three metabolic GRSs and macronutrient in-
take on the development of type 2 diabetes. All three GRSs
were positively associated with incident type 2 diabetes [3–5]
and the associations between macronutrient intake and type 2
diabetes were directionally consistent with previous literature
(Table 1) [7–9].
The literature on gene–macronutrient interaction studies
and type 2 diabetes, using a GRS, is limited. A cross-
sectional study which examined the interaction between a type
2 diabetes GRS and carbohydrate and fibre intake failed to
identify interactions for prevalent type 2 diabetes (N = 1337
cases of type 2 diabetes) [10]. Our work is the first to examine
gene–macronutrient interactions for type 2 diabetes risk pro-
spectively using three GRSs, comprehensively investigating
all major macronutrients, and consists of a large sample (N =
9742 cases of type 2 diabetes). The consistency across various
methods (adoption of unweighted and weighted GRSs, com-
bined GRSs as well as their constituent SNPs and application
of isocaloric macronutrient substitutionmodelling) collectively
strengthens the confidence in our null findings for interaction.
Table 1 Main association between macronutrient intake or GRS and incidence of type 2 diabetes: EPIC-InterAct study
Variable No. cases/total Subcohort non-cases Total incident T2D cases HR (95% CI) per SDa
Median follow-up, years 9742/21,900 12.3 6.8
Age at baseline, years 52.3 (9.3) 55.7 (7.6)
Sex, % male 37.9 49.9
Macronutrient intake
Carbohydrate, % TEI 9742/21,900 44.1 (6.9) 43.7 (6.9) 0.97 (0.92, 1.02)
Protein, % TEI 9742/21,900 16.9 (3.0) 17.2 (3.0) 1.10 (1.03, 1.18)
Animal protein, % TEI 9742/21,900 10.5 (3.2) 10.9 (3.2) 1.10 (1.01, 1.18)
Plant protein, % TEI 9742/21,900 5.0 (1.3) 4.9 (1.3) 1.074 (0.999, 1.150)
Fat, % TEI 9742/21,900 34.8 (5.7) 34.7 (5.7) 1.03 (0.99, 1.08)
SFA, % TEI 9742/21,900 13.4 (3.3) 13.3 (3.3) 0.99 (0.93, 1.06)
MUFA, % TEI 9742/21,900 13.1 (3.4) 13.0 (3.4) 1.04 (0.97, 1.12)
PUFA, % TEI 9742/21,900 5.5 (1.8) 5.6 (1.8) 1.066 (0.999, 1.137)
Fibre, g 9742/21,900 22.7 (7.5) 22.6 (7.6) 0.92 (0.84, 1.02)
Cereal, g 9739/21,891 8.8 (4.9) 8.9 (4.9) 0.96 (0.86, 1.07)
Fruit, g 9608/21,611 4.3 (3.2) 4.2 (3.2) 0.86 (0.73, 1.02)
Vegetable, g 9737/21,893 4.1 (2.6) 34.0 (2.6) 0.99 (0.94, 1.04)
GRS
T2D (per 4.3 risk alleles) – – – 1.49 (1.37, 1.63)
IR (per 4.5 risk alleles) – – – 1.14 (1.09, 1.20)
BMI (per 6.3 risk alleles) – – – 1.07 (1.04, 1.10)b
Data are means (SD) unless stated otherwise
HRs for macronutrients (per SD) and incident T2D: carbohydrate intake adjusted for age (underlying time scale), sex, centre, education, physical activity,
smoking status, sex-specific alcohol category, BMI, TEI, dietary protein, PUFA:SFA ratio, dietary fibre (attempt to replicate model 3 in Sluijs et al [7]);
intake of protein and its subtypes adjusted for age (underlying time scale), sex, centre, physical activity, smoking status, sex-specific alcohol category,
BMI, waist–hip ratio, TEI, dietary fibre, SFA, MUFA, PUFA, soft drinks, tea and coffee (not adjusted for carbohydrates; i.e. a substitution model),
education (attempt to replicate model 4 in van Nielen et al [8]); intake of fat and its subtypes adjusted for age (underlying time scale), sex, centre, physical
activity, smoking status, sex-specific alcohol category, BMI, TEI, dietary fibre, magnesium, iron, vitamin C, leafy vegetables, tea, coffee, education;
intake of dietary fibre and its subtypes adjusted for age (underlying time scale), sex, centre, physical activity, smoking status, sex-specific alcohol
category, TEI, dietary carbohydrates, magnesium, saturated fatty acids, education level. Fibre subtypes were mutually adjusted (attempt to replicate
model 3 in The InterAct Consortium, 2015 [9]). HR for GRSs and T2D: adjusted for age (underlying time scale), sex, centre, first five principal
components for population stratification and BMI. No. of SNPs: T2D 48 (as per Morris et al [3]), BMI 97 (as per Locke et al [4]), IR 53 (as per
Lotta et al [5])
a SD calculated based on the whole population
b BMI GRS does not include adjustment for BMI
IR, insulin resistance; MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid; T2D, type 2 diabetes; TEI, total
energy intake
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There are several factors that may contribute to the absence
of interactions in our current study. Other dietary exposures,
such as foods and/or dietary patterns, may offer greater insight
compared with nutrients based on the food synergism hypoth-
esis and may be subject to less accumulated measurement
error. There may also be other genetic loci, with no or weak
marginal genetic effects for our traits of interest, that may
show a significant variation in effect between subgroups of
the population. A GRS may mask interactions with individual
SNPs and so may reduce statistical efficiency. Therefore, we
also examined individual SNP interactions but did not identify
any that were statistically significant. The generalisability of
our findings is limited to European populations and research is
warranted in other populations.
Among this study’s strengths, EPIC-InterAct’s prospec-
tive design minimises the potential bias due to recall bias
and reverse causality for dietary exposures and the verifi-
cation of diabetes cases minimises possible misclassifica-
tion bias of the outcome. To our knowledge, this study
represents the most comprehensive investigation of the in-
teraction between multiple GRSs and macronutrient intake
on incident type 2 diabetes, to date. We tried to address
some of the key methodological issues identified from
our recent systematic review, including multiple testing
and inadequate control for likely confounders [1]. To re-
duce the risk of spurious gene–macronutrient interactions,
we confirmed that the GRSs were not correlated with mac-
ronutrient intake. To our knowledge, this is also the first
observational study of gene–macronutrient interactions
within the cardiometabolic literature that has investigated
the effect of isocaloric macronutrient substitution, which is
important for public health interpretation of macronutrient
density.
In conclusion, within a multi-centre European cohort, we
observed no interaction between GRSs for type 2 diabetes,
insulin resistance and BMI and macronutrient intake on the
risk for developing type 2 diabetes. These findings suggest
that currently there is no support for personalised dietary ad-
vice on macronutrient intake for type 2 diabetes prevention in
subgroups of the population defined by their overall genetic
risk for type 2 diabetes, insulin resistance or BMI.
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